CLINICAL TRIALS PROFILE FOR BANZEL
✉ Email this page to a colleague
All Clinical Trials for BANZEL
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00334958 ↗ | Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures | Completed | Eisai Inc. | Phase 3 | 2006-02-13 | To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BANZEL
Condition Name
Clinical Trial Locations for BANZEL
Trials by Country
Clinical Trial Progress for BANZEL
Clinical Trial Phase
Clinical Trial Sponsors for BANZEL
Sponsor Name